PARP Inhibitor Therapy

PARP inhibitor therapy is an oral or intravenous cancer treatment that blocks PARP proteins and can prevent certain cancer cells from repairing damaged DNA. It is a targeted systemic treatment: the medicine travels through the bloodstream and may be used after other treatment, as maintenance therapy, or for cancer that has returned. The choice depends on the cancer type, previous treatment, overall health, and tumour biology.

Your oncology team confirms the indication, reviews medicines and health conditions, and may test tumour or inherited genes involved in DNA repair. You take tablets on a prescribed schedule, or receive medicine through a vein when that formulation is selected. Blood tests help monitor blood counts, kidney function, and liver function. Do not change the dose or stop treatment without speaking with the prescribing team.

Common effects can include tiredness, nausea, reduced appetite, indigestion, headache, and changes in blood counts. Tell the team promptly about fever, unusual bruising or bleeding, breathlessness, chest discomfort, severe weakness, or persistent vomiting. Rare blood or bone-marrow problems can be serious, so scheduled tests and timely reporting matter.

PARP inhibitors can delay cancer growth or help control disease in people whose tumours are sensitive to impaired DNA repair. Benefit is not identical for everyone and depends on tumour features, prior therapy, and how the cancer responds. Your clinician can explain the treatment goal, how response will be assessed, and when a different approach may be considered.

These medicines work throughout the body rather than at one tumour site. Some people continue them while they are helping and side effects remain manageable. Interactions with other medicines can matter, and pregnancy planning should be discussed before treatment.

PARP inhibitor therapy may be considered for selected people with ovarian cancer, pancreatic cancer, or triple-negative breast cancer, particularly when tumour testing or treatment history suggests a DNA-repair weakness. A genetic finding alone does not determine the plan; the cancer type, current disease status, and approved options are also reviewed.

The team explains the aim and schedule, checks baseline blood and organ function, reviews other medicines, starts the selected dose, and arranges follow-up tests. At visits, report symptoms clearly so the team can adjust timing, provide supportive care, or investigate a new problem.

There is usually no procedure wound because treatment is medicine-based. Fatigue or nausea may appear during treatment and can improve with supportive care or a dose change. Follow-up continues with appointments, blood tests, and scans when appropriate; the timing is individual.

The main safety concerns are low blood counts, infection risk, anaemia, kidney or liver effects, and interactions with other medicines. Seek urgent medical advice for severe breathlessness, fainting, uncontrolled bleeding, or a high temperature. Keep an up-to-date medicine list.

Depending on the cancer and treatment goal, options may include chemotherapy, hormone treatment, immunotherapy, another targeted medicine, surgery, radiotherapy, or supportive care. Ask how each option fits your tumour findings and priorities.

Look for an oncology service that can review tumour testing, manage oral cancer medicines, arrange blood monitoring, and coordinate pharmacy support. Bring pathology reports, scan results, and your complete medicine list to the consultation. Read more about Ovarian Cancer, Pancreatic Cancer, Triple-Negative Breast Cancer, and PARP Inhibitor Drugs.